Research Progress on the Mechanism of Anti-Tumor Immune Response Induced by TTFields

被引:3
|
作者
Lan, Yue [1 ,2 ,3 ,4 ]
Zhang, Shaomin [2 ,3 ,4 ]
Pan, Yun [5 ]
Wang, Minmin [2 ,3 ,4 ,6 ]
Chen, Guangdi [1 ]
机构
[1] Zhejiang Univ, Dept Publ Hlth, Sch Med, Hangzhou 310027, Peoples R China
[2] Zhejiang Univ, Dept Biomed Engn, Qiushi Acad Adv Studies, Hangzhou 310027, Peoples R China
[3] Zhejiang Univ, Key Lab Biomed Engn, Minist Educ, Hangzhou 310027, Peoples R China
[4] Zhejiang Univ, Zhejiang Prov Key Lab Cardiocerebral Vasc Detect T, Hangzhou 310027, Peoples R China
[5] Zhejiang Univ, Coll Informat Sci & Elect Engn, Hangzhou 310027, Peoples R China
[6] Zhejiang Univ, Binjiang Inst, Hangzhou 310027, Peoples R China
基金
国家重点研发计划;
关键词
tumor treating fields; mechanism of action; anti-tumor immunity; immunotherapy; TUMOR-TREATING FIELDS; RANDOMIZED PHASE-III; GLIOBLASTOMA; TEMOZOLOMIDE; THERAPY; IMMUNOSURVEILLANCE; CHEMOTHERAPY; NOVOTTF-100A; SURVIVAL; TRIAL;
D O I
10.3390/cancers15235642
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Although conventional and emerging treatment modalities have improved the survival outcomes of cancer patients to some extent, the prognosis for solid tumors remains notably grim. Tumor treating fields, as a novel approach for cancer therapy, have shown promising effects as both a monotherapy and in combination with chemotherapy. However, the underlying mechanisms through which TTFields exert their anticancer effects remain incompletely understood. In recent years, many researchers have suggested that inducing anti-tumor immune responses may be one of the key mechanisms of the anticancer activity of TTFields. Several clinical trials are currently exploring the combination of TTFields with tumor immunotherapy and have achieved positive results. This article reviews the research progress on the mechanisms of TTFields-induced anti-tumor immune responses and discusses their clinical significance. The objective is to offer a streamlined and precise summary to facilitate the future exploration and advancement of TTFields.Abstract Tumor treating fields (TTFields), a biophysical therapy technology that uses alternating electric fields to inhibit tumor proliferation, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of newly diagnosed or recurrent glioblastomas (GBM) and malignant pleural mesotheliomas (MPM). Clinical trials have confirmed that TTFields are effective in slowing the tumor growth and prolonging patient survival. In recent years, many researchers have found that TTFields can induce anti-tumor immune responses, and their main mechanisms include upregulating the infiltration ratio and function of immune cells, inducing the immunogenic cell death of tumor cells, modulating immune-related signaling pathways, and upregulating the expression of immune checkpoints. Treatment regimens combining TTFields with tumor immunotherapy are emerging as a promising therapeutic approach in clinical practice. Given the increasing number of recently published studies on this topic, we provide an updated review of the mechanisms and clinical implications of TTFields in inducing anti-tumor immune responses. This review not only has important reference value for an in-depth study of the anticancer mechanism of TTFields but also provides insights into the future clinical application of TTFields.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Research progress on anti-tumor immune effect of cryoablation
    Liu, Ying
    Huang, Tao
    Shen, Lujun
    Wu, Ying
    Chen, Shuanggang
    Fan, Weijun
    CHINESE JOURNAL OF ACADEMIC RADIOLOGY, 2022, 5 (02) : 74 - 81
  • [2] Research progress on anti-tumor immune effect of cryoablation
    Ying Liu
    Tao Huang
    Lujun Shen
    Ying Wu
    Shuanggang Chen
    Weijun Fan
    Chinese Journal of Academic Radiology, 2022, 5 : 74 - 81
  • [3] Research progress on anti-tumor mechanism of TAOK kinases
    Li, Jilei
    Wei, Xindong
    Dong, Zhixin
    Fu, Yi
    Ma, Yujie
    Wu, Hailong
    CELLULAR SIGNALLING, 2024, 124
  • [4] Tumor treating fields (TTFields) induce an anti-tumor immune response in a pancreatic cancer mouse model
    Kan, Tal
    Khalil, Tharwat Haj
    Barsheshet, Yiftah
    Voloshin, Tali
    Vorontsov, Avital
    Brant, Boris
    Koren, Lilach
    Blatt, Roni
    Cahal, Shay
    Zemer-Tov, Efrat
    Paz, Rom
    Klein-Goldberg, Anat
    Brami, Catherine Tempel
    Jacobovitch, Sara
    Volodin, Alexandra
    Koltun, Bella
    David, Cfir
    Haber, Adi
    Giladi, Moshe
    Weinberg, Uri
    Palti, Yoram
    CANCER RESEARCH, 2024, 84 (06)
  • [5] Research Progress Evaluating the Function and Mechanism of Anti-Tumor Peptides
    Pan, Xinxing
    Xu, Juan
    Jia, Xuemei
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 397 - 409
  • [6] The immune system as anti-tumor sentinel: Molecular requirements for an anti-tumor immune response
    Markiewicz, MA
    Gajewski, TF
    CRITICAL REVIEWS IN ONCOGENESIS, 1999, 10 (03): : 247 - 260
  • [7] The role of innate immune cells in the tumor microenvironment and research progress in anti-tumor therapy
    Lu, Chenglin
    Liu, Ying
    Ali, Nasra Mohamoud
    Zhang, Bin
    Cui, Xiaonan
    FRONTIERS IN IMMUNOLOGY, 2023, 13
  • [8] Treatment induced upregulation of DNA sensing pathways as a mechanism for inducing anti-tumor immune response
    Jesenko, T.
    Bosnjak, M.
    Markelc, B.
    Sersa, G.
    Znidar, K.
    Heller, L.
    Cemazar, M.
    FEBS OPEN BIO, 2021, 11 : 98 - 99
  • [9] Tumor treating fields (TTFields) elicit an anti-tumor immune response and in combination enhance anti-PD-1 treatment efficacy
    Kaynan, Noa
    Voloshin, Tali
    Davidi, Shiri
    Porat, Yaara
    Shteingauz, Anna
    Munster, Mijal
    Schneiderman, Rosa
    Giladi, Moshe
    Weinberg, Uri
    Palti, Yoram
    CANCER RESEARCH, 2020, 80 (16)
  • [10] Tumor ablation induced anti-tumor immunity: destruction of the tumor in situ with the aim to evoke a robust anti-tumor immune response
    Keisari, Yona
    Kelson, Itzhak
    CANCER AND METASTASIS REVIEWS, 2023, 42 (04) : 1065 - 1068